PTGX Dec 2024 20.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

5.60

0.00

(0.00%)

At close: 12:53PM EDT

Loading interactive chart...

Simply Wall St.
Despite shrinking by US$82m in the past week, Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 188% over 5 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
ACCESSWIRE
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and ...
Zacks
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 0% and 89.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?